Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report report published on Sunday. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix Price Performance

PULM opened at $7.20 on Friday. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $8.44. The stock’s 50 day moving average price is $5.20 and its 200 day moving average price is $3.18. The stock has a market cap of $26.29 million, a P/E ratio of -2.73 and a beta of 1.52.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.